Abstract
Diabetic neuropathy (DN), particularly diabetic peripheral neuropathy (DPN), is one of the most common and debilitating complications of diabetes mellitus. Its multifactorial pathogenesis—driven by hyperglycaemia-induced oxidative stress, inflammation, mitochondrial dysfunction, advanced glycation end-products (AGEs), and microvascular insufficiency—offers several molecular targets for intervention. Polyphenols, a diverse class of plant-derived phenolic compounds (e.g., flavonoids, stilbenes, phenolic acids, and catechins), exhibit pleiotropic biological activities relevant to DN: antioxidant and free-radical scavenging, modulation of redox-sensitive transcription factors (Nrf2, NF-κB), inhibition of AGE formation, mitochondrial protection, and regulation of neuroinflammation and microglial function. Preclinical (in vitro and animal) studies consistently show neuroprotective effects for specific polyphenols—resveratrol, curcumin, epigallocatechin gallate (EGCG), quercetin, catechins and cocoa flavanols—across endpoints such as nerve conduction velocity, pain behaviours, axonal integrity, and biochemical markers of oxidative stress and inflammation. Clinical evidence is promising but mixed: some randomized trials (e.g., nano-curcumin) reported symptomatic and biochemical improvements while more recent larger/longer trials show equivocal results—highlighting challenges of bioavailability, standardization, dosing, and heterogeneity of outcome measures. Innovative delivery systems (nanoparticles, phytosome/complexes), combination approaches, and rigorously designed randomized controlled trials with standardized endpoints are needed to translate preclinical promise into clinical practice. This review synthesizes mechanisms of action, summarizes key preclinical and clinical evidence, outlines limitations, and presents recommendations for future research.